Boehringer secures Patent Injunction for its Diabetes Drug – Empagliflozin
The Himachal Pradesh High Court has granted Boehringer Ingelheim an interim injunction against Eris Lifesciences, preventing the manufacture and sale of Empagliflozin during the suit. The case provides…